KPMW135

KPMW135 is an investigational **CD20 x CD3 bispecific antibody-based immunotherapy** developed by Kleo Pharmaceuticals using its MATE conjugation platform. The molecule is generated by chemically conjugating a CD3-directed single-chain variable fragment derived from SP34 to rituximab, thereby preserving rituximab's native CD20 binding and Fc receptor interactions while adding T-cell redirection against CD20-positive malignant B cells. The program is intended for B-cell malignancies, particularly B-cell lymphomas and lymphocytic leukemias, where it is designed to combine rituximab-mediated antitumor activity with induced T cell-mediated cytotoxicity.

Other names

CD20 x CD3 bispecific moleculeCD-20 x CD3 bispecific moleculeCD 20 x CD3 bispecific moleculerituximab conjugated to CD3-directed ScFv SP34